Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.60 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13836265 | 1.00 | OPRM1 (0.60) | OPRM1ESR1ESR2OPRK1MAPK1 | |
| SCHEMBL12658289 | 0.83 | GFER (0.55) | MAPK1GFERPOLBLMNASMN1; SMN2 | |
| SCHEMBL29914715 | 0.81 | OPRM1 (0.70) | OPRM1MAPK1DRD2 | |
| SCHEMBL28436447 | 0.81 | OPRM1 (0.70) | OPRM1MAPK1DRD2 | |
| SCHEMBL21227034 | 0.81 | OPRM1 (0.70) | OPRM1MAPK1DRD2 | |
| SCHEMBL5632211 | 0.81 | ADAMTS5 (0.47) | MAPK1DRD2GFERPOLBSMN1; SMN2 | |
| SCHEMBL5630915 | 0.81 | ADAMTS5 (0.47) | MAPK1DRD2GFERPOLBSMN1; SMN2 | |
| SCHEMBL27629652 | 0.81 | C1S (0.49) | MAPK1 | |
| SCHEMBL5630922 | 0.81 | ADAMTS5 (0.47) | MAPK1DRD2GFERPOLBSMN1; SMN2 | |
| SCHEMBL27629653 | 0.81 | C1S (0.49) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9750738-B2 | Arylpiperazine opioid receptor antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2017-09-05 | — | — | US | disclosed |
| US-9750738-B2 | Arylpiperazine opioid receptor antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2017-09-05 | — | — | US | disclosed |
| US-9750738-B2 | Arylpiperazine opioid receptor antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160095854-A1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160095854-A1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160095854-A1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2016-04-07 | — | — | US | disclosed |
| US-9273027-B2 | Arylpiperazine opioid receptor antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273027-B2 | Arylpiperazine opioid receptor antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273027-B2 | Arylpiperazine opioid receptor antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2016-03-01 | — | — | US | disclosed |
| EP-2539706-B1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | RES TRIANGLE INST (US) | 2015-03-04 | — | — | EP | disclosed |
| EP-2539706-B1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | RES TRIANGLE INST (US) | 2015-03-04 | — | — | EP | disclosed |
| EP-2539706-A1 | ARYLPIPERAZONE OPIOID RECEPTOR ANTAGONISTS | Research Triangle Institute (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120295919-A1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295919-A1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295919-A1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2011106039-A1 | ARYLPIPERAZONE OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011106039-A1 | ARYLPIPERAZONE OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295919-A1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRD1 | OPRM1 2/4885ESR1 344/4885ESR2 219/4885 |
| US-20160095854-A1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRD1 | OPRM1 2/4885ESR1 331/4885ESR2 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.